Neutralizing capacity of monoclonal and polyclonal anti-natalizumab antibodies: The immune response to antibody therapeutics preferentially targets the antigen-binding site

Karin A. van Schie, Simone Kruithof, Pauline A. van Schouwenburg, Anke Vennegoor, Joep Killestein, Gertjan Wolbink, Theo Rispens

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1035-1037.e6
JournalJournal of Allergy and Clinical Immunology
Volume139
Issue number3
DOIs
Publication statusPublished - 1 Mar 2017

Cite this